Abstracts Archive - Page 45 of 2607 - ACR Meeting Abstracts

Abstract Number: 0766 • ACR Convergence 2025
Effects of Walking During the 6-Minute Walk Test on Cognition in Adults with Knee Replacement
Christine Pellegrini¹, Jongwon Lee¹, Chih-Hsiang Yang¹, Scott Jamieson², Clare Kennerley¹ and Sara Wilcox¹, ¹University of South Carolina, Columbia, SC, ²The University of South Carolina, Columbia, SC
Background/Purpose: The majority of adults with knee replacement remain physically inactive after surgery and are at high risk for Alzheimer’s and related dementias (ADRD). This…
Abstract Number: 0503 • ACR Convergence 2025
Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
Andrey E. Karateev¹, Sofia Kuzkina², Alina Egorova³ and Elena Y. Polishchuk¹, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²R-Pharm, Moscow, Russia, ³R-Pharm JSC, Moscow, Russia
Background/Purpose: Pain is one of the most debilitating symptoms of rheumatoid arthritis (RA) and a major contributor to reduced quality of life. Persistent joint pain…
Abstract Number: 0529 • ACR Convergence 2025
Anti-PeptidylArginine Deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
Ana-Maria Orbai¹, Hong Wang², Maria Grecu³, Ning Meng⁴, Ji Soo Kim⁵, Clifton Bingham⁴, Uzma Haque², John Miller⁴, Felipe Andrade², Erika Darrah⁶ and Eleni Tiniakou⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³River Hill High School, Clarksville, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Astra Zeneca, Gaithersburg, MD, ⁷UT Health Science Houston, Houston, TX
Background/Purpose: Citrullinated cathelicidin (LL37), a human-derived antimicrobial peptide, is an autoantigen in psoriatic arthritis (PsA).1 LL37 citrullination by peptidylarginine deiminase (PAD) enzymes attenuates immune activation…
Abstract Number: 0738 • ACR Convergence 2025
Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis
Anisha Dua¹, Aditi Kadakia², Patrick Zueger³, Simran Marwaha⁴, Nathaniel Zerad³, Arathi Setty³, William Jones⁴ and Valerie Devauchelle⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²AbbVie Inc, Woburn, MA, ³AbbVie Inc, North Chicago, IL, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵UBO, Brest, France
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in patients 50 years and older. Glucocorticoids (GC) are the mainstay of treatment for GCA…
Abstract Number: 0754 • ACR Convergence 2025
Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients
Milena Bond¹, Philipp Bosch², Aaron Juche³, Hans Bastian³ and Wolfgang Schmidt⁴, ¹South Tyrol Health Trust and Teaching Hospital of the Paracelsus Medical University, Brunico, Italy, ²Medical University of Graz, Graz, Austria, ³Rheumaklinik Berlin-Buch, Berlin, Germany, ⁴Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany
Background/Purpose: Whether the disease onset in giant cell arteritis (GCA) exhibits a seasonal pattern remains unclear. Previous studies have yielded conflicting evidence: some report no…
Abstract Number: 0787 • ACR Convergence 2025
The Cost-effectiveness of Physical Therapy for Patients with Meniscal Tear and Osteoarthritis
Samantha Chin¹, Sasha Aronson¹, Jamie Collins¹, Faith Selzer¹, Ying Heidi Yang¹, Leslie Bisson², Antonia Chen³, Morgan Jones⁴, Clare Norton¹, Karen Smith¹, Kurt Spindler⁵, Jeffrey Katz⁶ and Elena Losina⁷, ¹Brigham and Women's Hospital, Boston, MA, ²University of Buffalo, Buffalo, ³Brigham and Women's Hospital, Newton, MA, ⁴Mass General Brigham, Boston, ⁵Cleveland Clinic, Cleveland, ⁶Brigham and Women's Hospital, Brookline, MA, ⁷BWH, Boston, MA
Background/Purpose: Based on several RCTs comparing outcomes of arthroscopic partial meniscectomy (APM) to non-operative management in persons with meniscal tears and OA, physical therapy (PT)…
Abstract Number: 0791 • ACR Convergence 2025
Disagreements in Disease Activity Measures in an Evaluation of SLE Outcome Measures in Telemedicine
Leila Khalili¹, Cynthia Aranow², Mimi Kim³, Diane Kamen⁴, Cristina Arriens⁵, Alberto Nordmann-Gomes⁶, Maya Souvignier⁶, Wei Tang⁷, Stephen Suh⁸, Maria Dall'Era⁹, Meghan mackay¹⁰ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Medical University of South Carolina, Johns Island, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Columbia University Irving Medical Center, New York, NY, ⁷Westchester Medical Center, Valhalla, NY, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Division of Rheumatology, University of California, San Francisco, CA, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We previously described the top-line results of our study and the high correlations between virtual SLE disease activity measures (DAM) and those obtained during…
Abstract Number: 0822 • ACR Convergence 2025
Clinical and Mechanistic Insight of Circulating Calprotectin and NXP2 autoantibodies in Juvenile Dermatomyositis
Kavya Sugur¹, Elizabeth Sloan², Emily Chong³, Sophia Matossian³, Katarina Kmetova⁴, Alyssa Rosek⁵, Christine Goudsmit⁶, Celine C. Berthier⁶, Pei-Suen Tsou³, Yu (Ray) Zuo³ and Jessica Turnier⁷, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³University of Michigan, Ann arbor, MI, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, ⁷University of Michigan, Saline, MI
Background/Purpose: Most children with juvenile dermatomyositis (JDM) have chronic disease despite multi-drug immunosuppression, highlighting the need for targeted therapies. Neutrophil extracellular traps (NETs) are key…
Abstract Number: 0818 • ACR Convergence 2025
Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Sachalee Campbell¹, Laura Daniel², Puran Nepa², Otis Wilson³, Alyson L. Dickson³, Katherine Murray³, William D. Dupont³, Adriana Hung³, Wayne A. Ray³, Michael Stein⁴ and Cecilia P. Chung², ¹University of Miami, Miami, FL, ²University of Miami, Research Service, Miami VA Healthcare System, Miami, FL, ³Vanderbilt University Medical Center, Vanderbilt, TN, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Pregabalin and duloxetine are among the most prescribed non-opioid medications for patients with chronic pain. Pregabalin may raise the risk for heart failure, and…
Abstract Number: 0745 • ACR Convergence 2025
Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study
Eugenio de Miguel, Natalia López-Juanes, Maria-Eugenia Miranda-Carus, Carlota Ureta, Chamaida Plasencia-Rodríguez and Irene Monjo Henry, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Traditionally, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) had been considered a hallmark of GCA and both are included in the 2022…
Abstract Number: 0806 • ACR Convergence 2025
Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
Teng-Chieh Hsu¹, An-Ping Huo², Pei-Lun Liao², Pui-Ying Leong² and James Wei³, ¹Wuri Lin Shin Hospital, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China)
Background/Purpose: Anifrolumab and belimumab are biologic agents approved for systemic lupus erythematosus (SLE), yet their comparative safety profiles, particularly regarding infection risks, remain inadequately characterized…
Abstract Number: 0736 • ACR Convergence 2025
Effectiveness of Tocilizumab in strokes in patients with giant cell arteritis. Spanish multicenter study of clinical practice
Ana Serrano-Combarro¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, Javier Narváez⁵, Vicente Aldasoro Cáceres⁶, Rafael B. Melero-González⁷, Isabel De la Morena⁸, Ivan Ferraz Amaro⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital León, LEON, Castilla y Leon, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁸HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA, VALENCIA, Spain, ⁹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Stroke is a feared complication of giant cell arteritis (GCA). Tocilizumab (TCZ) has shown efficacy and safety in large-vessel vasculitis (LVV) including GCA. Our…
Abstract Number: 0749 • ACR Convergence 2025
Prevalence and characteristics of subclinical Polymyalgia Rheumatica in patients with Giant Cell Arteritis
Javier Narváez¹, Paola Vidal-Montal², Martí Aguilar-Coll³, Montserrat Roig Kim⁴, Laia De Daniel Bisbe⁴, Monica Cubells⁵, Aina Fabregat⁶, Judith Palacios-Olid³, Pol Maymó-Paituvi⁴, Carmen Moragues³ and Joan Miquel Nolla⁴, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁵Hospital Universitari de Bellvitge, Barcelona, Spain, ⁶Department of Rheumatology. Hospital Universitario de Bellvitge., Barcelona, Spain
Background/Purpose: In clinical practice, 18F-FDG PET-CT often reveals findings suggestive of polymyalgia rheumatica (PMR) in patients with giant cell arteritis (GCA) who lack symptoms or…
Abstract Number: 0536 • ACR Convergence 2025
Can achieving sustained low disease activity through treat-to-target management arrest enthesiophyte progression in psoriatic arthritis? A two-year prospective study using high resolution peripheral quantitative computed tomography
Isaac Cheng¹, Ho So¹, Yingzhao jin¹, Vivian Hung², Ling Qin², James Griffith³ and Lai Shan Tam¹, ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Bone Quality and Health Centre, Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Enthesitis is a hallmark feature of psoriatic arthritis (PsA). Chronic inflammation in the entheses can lead to the formation of enthesiophytes (bony spurs), and…
Abstract Number: 0734 • ACR Convergence 2025
Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
Julie Mouchet¹, Lauren Revie², Tim Nguyen³, Liwei Zhao⁴, Valeria Jordan M.⁵, G S Ramakrishna⁶, Linda Grinnell-Merrick³, Atif Adam⁷ and Minouk Schoemaker⁸, ¹Novartis Pharma AG, Basel, Switzerland, ²IQVIA, EMEA, London, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴IQVIA, Real World Solutions, Mölndal, Sweden, ⁵Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷IQVIA Inc, Boston, ⁸IQVIA, Real World Solutions, Amsterdam, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions that predominantly affect individuals ≥50 years of age. The conditions share overlapping…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].